ArticlePloS one2016
CD271+ Mesenchymal Stem Cells as a Possible Infectious Niche for Leishmania infantum.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Leishmania amazonensis amastigotes invade non-phagocytic cells via highly localized parasite-induced actin remodeling.PLoS neglected tropical diseases · 2026Article
- New insights into the life cycle, host cell tropism, and infection amplification ofInfection and immunity · 2025Review
- The Parasitemia has Contributed to the Severity of Cases of Visceral Leishmaniasis.Indian journal of microbiology · 2024Article
- Article
- Unrevealing the Mystery of Latent Leishmaniasis: What Cells Can HostPathogens (Basel, Switzerland) · 2023Review
- Elucidating the role played by bone marrow in visceral leishmaniasis.Frontiers in cellular and infection microbiology · 2023Review
- Long-term hematopoietic stem cells as a parasite niche during treatment failure in visceral leishmaniasis.Communications biology · 2022Article
- Delineating the role of extracellular vesicles in cancer metastasis: A comprehensive review.Frontiers in immunology · 2022Review
- Review of the potential of mesenchymal stem cells for the treatment of infectious diseases.World journal of stem cells · 2021Review
- Unexpected encounter of the parasitic kind.World journal of stem cells · 2019Review
- Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models.PLoS neglected tropical diseases · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL) is a serious and fatal disease. Therapeutic drugs are toxic and non-sterilizing. The etiological agents Leishmania infantum and Leishmania donovani cause active and asymptomatic diseases. Effective drugs to treat VL exist but unfortunately, post-treatment relapses are common. Little is known why drugs are non-sterilizing or how these intracellular pathogens can escape treatment. Here, using a murine model of VL we found that CD271+/Sca1+ bone marrow mesenchymal stem cells (BM-MSCs) are readily infected in vitro and in vivo by L. infantum. Because BM-MSCs express potent drug efflux pumps, e.g., ABCG2 it is possible that this unique intracellular infectious niche could allow L. infantum to escape anti-parasite drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.